NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an …
Full NKGN analysis →
Competitive advantage assessment
Key strengths
ROIC Sustainably Above PeersROIC at 90.7th percentile exceeds peers and WACC, demonstrating superior capital allocation.
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 35.1th percentile with high volatility suggests weak pricing power or commoditized products.
NKGen Biotech, Inc. ranks #575 of 713
scored companies in Biotechnology by moat score — the top 81%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near NKGN in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 9
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 9
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 91
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 18
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 22
· 15% of the moat score
Scale matters only when it converts into economics.
NKGen Biotech, Inc. (NKGN) scores 24 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #575 of 713 scored companies in Biotechnology, the top 81%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (91/100) and its weakest is Customer Stickiness (9/100).
How does NKGen Biotech, Inc. compare with other Biotechnology companies?
NKGen Biotech, Inc. ranks #575 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are NanoViricides, Inc. (NNVC) at 24 just above it and Allogene Therapeutics, Inc. (ALLO) at 24 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is NKGen Biotech, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for NKGen Biotech, Inc.?
The Corporate Default template measures 6 defenses, and NKGN scores: Pricing Power (11), Cost Advantage (9), Customer Stickiness (9), Capital Efficiency (91), Resilience (18), Scale & Market Position (22). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.